Clinical Trial

Clinical Study of BCMA/CD70-targeted CAR-T Therapy for Refractory Pediatric Rheumatic Diseases

Recruiting Phase 1
View on ClinicalTrials.gov →
Record status
This record was last updated September 19, 2025 (before its estimated March 30, 2026 completion). Its status may not reflect the trial's current state.
Summary
This is an investigator-initiated trial to evaluate the efficacy and safety of BCMA/CD70-targeted CAR-T in the treatment of refractory pediatric rheumatic diseases.
Trial Details
NCT Number NCT07184450
Lead Sponsor Chongqing Precision Biotech Co., Ltd
Conditions Juvenile Dermatomyositis (JDM), Polyarticular Juvenile Idiopathic Arthritis, Systemic Sclerosis (SSc), Primary Sjogren's Syndrome
Enrollment 11 participants
Start Date 2025-09-01
Primary Completion 2026-03-30 (estimated)
Study Completion 2028-09-30 (estimated)
Updated on ClinicalTrials.gov 2025-09-19